Tau and amyloid show distinct relationships with cognitive decline in Alzheimer's disease: A multimodal PET-MRI study
Open Access
- 29 October 2026
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 10
Abstract
Background: Amyloid-β (Aβ) and tau show distinct relationships with brain injury in Alzheimer's disease. We evaluated if tau-associated MRI abnormalities persist after accounting Aβ and compared multimodal MRI with PET for classifying cognitive impairment. Multi-parametric MRI provides an accessible framework to capture complementary macrostructural, microstructural, and biophysical tissue alterations across the disease continuum. Objective: To determine whether continuous global cortical tau burden independently relates to regional multi-parametric MRI metrics after controlling for Aβ, and to evaluate how effectively quantitative MRI versus PET markers reflect cognitive status and impairment. Methods: Forty-four participants underwent amyloid/tau PET and advanced MRI (T1 volumetry, DTI, QSM, T1ρ). Covariate-adjusted multivariable linear regressions examined associations of global amyloid and tau burden with regional MRI measures. Mediation and ROC analyses were exploratory. Results: After adjustment for Aβ, higher tau was nominally associated with lower amygdala and putamen fractional anisotropy, but no association survived FDR correction. Conversely, higher Aβ was associated with smaller hippocampal and amygdala volumes and higher hippocampal mean diffusivity, which partly mediated poorer MoCA and HKLLT performance. Hippocampal volume (AUC = 0.949) and mean diffusivity (AUC = 0.928) outperformed tau PET (AUC = 0.733) for classifying cognitive impairment. Conclusions: All cognitively impaired participants were tau-positive, but continuous tau burden showed no clear association with cognition. Hippocampal MRI markers better reflected clinical status.Keywords
This publication has 36 references indexed in Scilit:
- Accuracy of the Montreal Cognitive Assessment tool for detecting mild cognitive impairment: A systematic review and meta‐analysisAlzheimer's & Dementia, 2023
- Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's diseaseHuman Brain Mapping, 2022
- Studies of aging nonhuman primates illuminate the etiology of early‐stage Alzheimer's‐like neuropathology: An evolutionary perspectiveAmerican Journal of Primatology, 2021
- The impact of amyloid‐beta and tau on prospective cognitive decline in older individualsAnnals of Neurology, 2019
- Defining imaging biomarker cut points for brain aging and Alzheimer's diseaseAlzheimer's & Dementia, 2016
- In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrumAnnals of Neurology, 2016
- Streaking artifact reduction for quantitative susceptibility mapping of sources with large dynamic rangeNMR in Biomedicine, 2015
- Synergistic Effect of β-Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal IndividualsJAMA Neurology, 2014
- Integrated Laplacian‐based phase unwrapping and background phase removal for quantitative susceptibility mappingNMR in Biomedicine, 2013
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011